Discussion forum: Challenging standard recommendations from a patient's, nurse's and physician's perspective
Martin Dreyling
Jack Richardson
Sarah Wells
08:30–08:35
WS Report: Learning through International Collaboration
Peter Borchmann
Alison Moskowitz
08:35–08:47
FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial
Wouter Plattel
08:47–09:00
Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
Peter Borchmann
09:15 – 10:15
Room: Großer Saal
Scientific SessionSpecial Situations in HL
Richard Hoppe
Marie Jose Kersten
09:15–09:35
HL in Pregnancy
Daan Dierickx
09:35–09:55
HIV-positive HL
Otavio Baiocchi
09:55–10:15
alloSCT in the era of anti-PD1
Anna Sureda
10:30 – 12:00
Room: Großer Saal
Scientific SessionGenomics, Biology and Microenvironment
Wolfram Klapper
Ralf Küppers
10:30–10:53
Biological Classification of HL by Liquid Biopsy
Sven Borchmann
10:53–11:16
Single Cell Transcriptomics of HL
Christian Steidl
WS Report: Bringing Liquid Biopsy to Patients
Sven Borchmann
Davide Rossi
Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
Kristiina Karihtala
High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years
Arjan Diepstra
Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade
Julia Paczkowska
12:15 – 13:45
Room: Großer Saal
Satellite Symposium
(by Takeda)
Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma
Graham Collins
Alex Herrera
Pier Luigi Zinzani
12:15–12:20
Welcome and introduction
Graham Collins
12:20–12:30
Hot off the press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHELON-1
Graham Collins
12:30–13:30
Bridging the gap: Balancing efficacy and toxicity in three challenging case studies (A debate and audience discussion with our panel)
Graham Collins
Alex Herrera
Pier Luigi Zinzani
13:30–13:40
Audience Q&A
13:40–13:45
Summary and close
Graham Collins
14:00 – 15:30
Room: Großer Saal
Scientific SessionRelapsed / Refractory HL
Ranjana Advani
Craig H. Moskowitz
14:00–14:23
1ˢᵗ Relapse of HL
Craig H. Moskowitz
14:23–14:46
Novel developments in R/R HL
Graham Collins
14:46–14:51
WS Report: PET beyond Deauville
Sally Barrington
Martin Hutchings
Carsten Kobe
14:51–15:04
Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
Anna Sureda
15:04–15:17
High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
Alison Moskowitz
15:17–15:30
Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
Catherine Diefenbach
15:30 – 16:00
Room: Großer Saal
Main ProgramClosing Remarks
15:30–16:00
Conference Highlights
Ranjana Advani
16:00 – 16:30
Room: Foyer (First Floor)
Main ProgramFarewell
ISHL12 Program at a Glance (PDF)
ISHL12 Final Program
This website uses cookies to ensure you get the best experience on our website.
By using our site you agree to our use of cookies.
Learn more